Apellis Gains FDA Approval for Empaveli to Treat Chronic Blood Disorder
Source: Streetwise Reports  (5/17/21)
Shares of Apellis Pharmaceuticals Inc. traded 20% higher after the company reported it received U.S. FDA approval for EMPAVELI (pegcetacoplan) for use in treatment of adults with paroxysmal nocturnal hemoglobinuria (PNH), a rare, chronic life-threatening blood disorder. More >

Analyst: Biotech Expecting a 'Catalyst-Rich' Second Half of the Year
Source: Streetwise Reports  (5/13/21)
An H.C. Wainwright & Co. report discusses Gritstone Bio's recent earnings and significant corporate events as the firm plans to release data on cancer and COVID-19 vaccines later this year.
More >

Pharma Developer Finds Ifenprodil Reduces Interleukin 6 in Phase 2b/3 COVID Trial
Source: Streetwise Reports  (5/13/21)
Algernon Pharmaceuticals reported that Ifenprodil was shown to reduce interleukin 6 in its Phase 2b/3 COVID-19 Study, which the company states may have positive implications for its use in its ongoing Phase 2 trial of Ifenprodil for treatment of idiopathic pulmonary fibrosis and chronic cough. More >

Life Sciences Firm Is at 'an Inflection Point with Significant Sales Increases Just around the Corner'
Source: Streetwise Reports  (5/12/21)
Noble Capital Markets noted in a research report that shortly after receiving its largest single order to date, a 4.4-ton order for OxC-beta Livestock, Avivagen Inc. has received a new order for 4 tons per month from its representative in Mexico. More >

Twist Bioscience Shares Wind Higher After Firm Posts 62% YoY Increase in Q2 Revenue
Source: Streetwise Reports  (5/7/21)
Shares of Twist Bioscience Corp. traded 14% higher after the firm reported that orders in Q2/21 grew by 69% year-over-year and that it is raising its FY/21 revenue guidance to $121–129 million. More >

Biotech's Gene Therapy Assets Put It 'Ahead of the Pack'
Source: Streetwise Reports  (5/5/21)
Sio Gene Therapies' focus and strategic portfolio are discussed in an H.C. Wainwright & Co. coverage initiation report. More >

BioNTech Shares Gain 11% on Filing COVID-19 Vaccine Expanded Use Request to EMA in Children Ages 12 to 15
Source: Streetwise Reports  (5/3/21)
BioNTech shares established a new 52-week high price after the company reported that together with its partner Pfizer it has filed a request to expand Conditional Marketing Authorization of COMIRNATY® in the EU to adolescents ages 12 to 15 for its mRNA-based SARS-CoV-2 vaccine.
More >

CryoLife Shares Trade 18% Higher on Q1 Financial Results
Source: Streetwise Reports  (4/30/21)
Shares of CryoLife Inc. set a new 52-week high intraday price after the company reported that total revenues in Q1/21 increased by 7% YoY to $71.1 million. More >

Galera Posts Positive Data from Phase 1/2 Pancreatic Cancer Trial
Source: Streetwise Reports  (4/29/21)
Galera Therapeutics shares traded 25% higher after the company reported new data from its Phase 1/2 pilot study of dismutase mimetic GC4419 that when used in combination with radiation therapy was shown to nearly double median overall survival time in patients with locally advanced pancreatic cancer. More >

Biopharma Study Shows Safety of Stem Cell Therapy in Severe COVID-19 Patients
Source: Streetwise Reports  (4/28/21)
The clinical trial, in which Sorrento Therapeutics established safety, and the company's next steps for this potential treatment are summarized in a Dawson James Securities report. More >

ADMA Biologics Granted FDA Approval to Boost IVIG Production by 50%
Source: Streetwise Reports  (4/28/21)
ADMA Biologics shares traded 9% higher after the company received FDA approval for increased intravenous immune globulin production scale, allowing the firm to increase manufacturing capacity from 400,000 to 600,000 liters and achieve peak revenues of greater than $300 million. More >

Aldeyra's Drug Meets All Key Endpoints in Phase 3 Allergic Conjunctivitis Trial
Source: Streetwise Reports  (4/27/21)
Aldeyra Therapeutics shares traded 33% higher after the firm reported that reproxalap significantly met all primary and secondary endpoints in its Phase 3 allergic conjunctivitis study. More >

Ocugen Reports $100 Million Direct Share Offering at Market Premium from Institutional Investors
Source: Streetwise Reports  (4/23/21)
Ocugen Inc. shares traded up as much as 47% before closing just 3.66% higher after the company announced a $100 million registered direct offering of common stock priced at a $10 per share, which represents a premium to the market price. More >

Is the Trend Turning for This Psychedelic Stock?
Source: Clive Maund for Streetwise Reports  (4/19/21)
Technical analyst Clive Maund charts Delic Inc. and explains why he considers the stock attractive at this point. More >

Ardelyx to Receive $5M Milestone Payment as Japan Partner Initiates Phase 3
Source: Streetwise Reports  (4/15/21)
Ardelyx Inc. shares traded 11% higher after Kyowa Kirin Co. Ltd., its collaborative partner in Japan, initiated four Phase 3 clinical trials of tenapanor for treatment of hyperphosphatemia. More >

Biotech Company Acquires Therapeutics Firm, Gains 'Gem' in the Portfolio
Source: Streetwise Reports  (4/14/21)
Dawson James Securities advised it is maintaining its "Buy" rating after Sorrento Therapeutics announced the acquisition of ACEA Therapeutics for $38 million in stock. More >

Novocure Shares Climb 50% on Acceleration of Phase 3 Lung Cancer Trial
Source: Streetwise Reports  (4/13/21)
Novocure Ltd. shares reached a new 52-week high after the company reported an update from its Phase 3 Pivotal LUNAR trial of tumor treating electrical fields in non-small cell lung cancer. More >

Affimed NV Shares Rise 20% on Initial Data from Phase 1 R/R CD30-Positive Lymphoma Trial
Source: Streetwise Reports  (4/9/21)
Affimed NV shares reached a new 52-week high price after the company presented initial data from a Phase 1 trial of its AFM13 that shows potential to help NK cells target and destroy cancer cells. More >

Gene Therapy Restoring Light Sensitivity 'Showed Impressive Dose-Response Improvements'
Source: Streetwise Reports  (4/7/21)
Roth Capital Partners advised that Applied Genetic Technologies co-development of BS01 with Bionic Sight "validates its gene therapy capabilities." More >

Biopharma's Phase 2b/3 Alzheimer's Disease Trial Approved to Continue
Source: Streetwise Reports  (4/7/21)
Anavex Life Sciences' study, its drug's mechanism of action and the company's upcoming catalysts are covered in a Dawson James Securities report. More >

Biohaven Expects Net Revenue of $43.8 Million in Q1 for Its Migraine Medicine
Source: Streetwise Reports  (4/7/21)
Biohaven Pharmaceutical shares traded 10% higher after the company reported that in Q1/21 net product revenue for its migraine drug NURTEC ODT is estimated to be approximately $43.8 million. More >

United Therapeutics Shares Rise 15% as FDA Clears Pathway to Launch Tyvaso to Treat PH-ILD
Source: Streetwise Reports  (4/1/21)
United Therapeutics shares reached a new 52-week high after the firm reported that the U.S. FDA granted approval to commercially launch its Tyvaso® Inhalation Solution to treat patients with pulmonary hypertension associated with interstitial lung disease. More >

Coverage Initiated on Health & Wellness Firm About to Launch Retail Sales, Sees 'Substantial Upside Potential'
Source: Streetwise Reports  (3/30/21)
Clarus Securities' initiation report on Rritual Superfoods views the company "as an attractive growth story for investors looking to gain exposure to a large and rapidly growing functional food and beverages market." More >

Pharmaceutical Development Company Added to First Psychedelic Stock Index ETF
Source: Streetwise Reports  (3/30/21)
Being included in the Horizons Psychedelic Stock Index Exchange Traded Fund will afford Algernon Pharmaceuticals greater investor exposure. More >

Data from Humanigen's Phase 3 COVID-19 Trial Show 54% Increase in Survival Rates
Source: Streetwise Reports  (3/29/21)
Shares of Humanigen Inc. traded 67% higher after the company reported positive topline results from its Phase 3 lenzilumabâ„¢ study indicating significant improvement in survival of hospitalized COVID-19 pneumonia patients without the need for mechanical ventilation. More >